Tonix Pharmaceuticals Holding annual shares outstanding
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Tonix Pharmaceuticals Holding Shares Outstanding History (TNXP)
Tonix Pharmaceuticals Holding reported 12.8M shares outstanding at the end of fiscal 2025.
View full Tonix Pharmaceuticals Holding company overviewTonix Pharmaceuticals Holding annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 12.8M | 8.4M | +191.57% |
| 2024 | 2024-12-31 | 4.4M | 4.4M | +20859.23% |
| 2023 | 2023-12-31 | 20,926 | −12.3M | −99.83% |
| 2022 | 2022-12-31 | 12.4M | −3.3M | −20.91% |
| 2021 | 2021-12-31 | 15.6M | −190.4M | −92.41% |
| 2020 | 2020-12-31 | 206.0M | 197.5M | +2314.68% |
| 2019 | 2019-12-31 | 8.5M | 8.2M | +2495.62% |
| 2018 | 2018-12-31 | 328,689 | 320,830.26 | +4082.46% |
| 2017 | 2017-12-31 | 7,858.74 | 3,939.559 | +100.52% |
| 2016 | 2016-12-31 | 3,919.181 | 2,036.014 | +108.12% |
| 2015 | 2015-12-31 | 1,883.167 | −8,922.053 | −82.57% |
| 2014 | 2014-12-31 | 10,805.22 | 4,982.139 | +85.56% |
| 2013 | 2013-12-31 | 5,823.081 | 3,663.922 | +169.69% |
| 2012 | 2012-12-31 | 2,159.159 | 805.809 | +59.54% |
| 2011 | 2011-12-31 | 1,353.35 | −16,681.133 | −92.50% |
| 2010 | 2010-12-31 | 18,034.483 | — | — |
Tonix Pharmaceuticals Holding quarterly shares outstanding
Q4.10
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
As of Nov 27, 2018
As of Nov 28, 2018
Q4.18
Q1.19
Q2.19
Q3.19
Q3.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q2.24
Q2.24
Q3.24
Q4.24
As of Feb 4, 2025
As of Feb 5, 2025
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 16.8M | 9.2M | +122.52% |
| Q1 2026 | 2026-03-31 | 14.2M | 7.3M | +106.54% |
| Q4 2025 | 2025-12-31 | 12.8M | 7.2M | +128.74% |
| Q3 2025 | 2025-09-30 | 10.2M | −548.9M | −98.18% |
| Q2 2025 | 2025-06-30 | 7.5M | 3.2M | +72.06% |
| Q1 2025 | 2025-03-31 | 6.9M | −148.8M | −95.58% |
| As of Feb 5, 2025 | 2025-02-05 | 5.6M | −4.2M | −43.14% |
| As of Feb 4, 2025 | 2025-02-04 | 559.0M | 556.1M | +18622.66% |
| Q4 2024 | 2024-12-31 | 4.4M | −91.2M | −95.41% |
| Q3 2024 | 2024-09-30 | 155.6M | 81.9M | +111.10% |
| Q2 2024 · Jun 30 | 2024-06-30 | 9.8M | −48.8M | −83.23% |
| Q2 2024 · Jun 10 | 2024-06-10 | 3.0M | −14.8M | −83.19% |
| Q2 2024 · Jun 9 | 2024-06-09 | 95.5M | 84.8M | +787.76% |
| Q1 2024 | 2024-03-31 | 73.7M | 10.0M | +15.76% |
| Q4 2023 | 2023-12-31 | 58.6M | −17.9M | −23.36% |
| Q3 2023 | 2023-09-30 | 17.8M | −35.6M | −66.69% |
| Q2 2023 | 2023-06-30 | 10.8M | −20.9M | −66.04% |
| Q1 2023 | 2023-03-31 | 63.7M | −489.1M | −88.48% |
| Q4 2022 | 2022-12-31 | 76.5M | −419.8M | −84.59% |
| Q3 2022 | 2022-09-30 | 53.3M | −350.4M | −86.79% |
| Q2 2022 | 2022-06-30 | 31.7M | −314.7M | −90.85% |
| Q1 2022 | 2022-03-31 | 552.8M | 228.9M | +70.67% |
| Q4 2021 | 2021-12-31 | 496.2M | 290.2M | +140.89% |
| Q3 2021 | 2021-09-30 | 403.7M | 263.5M | +188.01% |
| Q2 2021 | 2021-06-30 | 346.4M | 337.8M | +3959.76% |
| Q1 2021 | 2021-03-31 | 323.9M | 274.6M | +556.33% |
| Q4 2020 | 2020-12-31 | 206.0M | 197.5M | +2314.68% |
| Q3 2020 | 2020-09-30 | 140.2M | 138.6M | +8797.63% |
| Q2 2020 | 2020-06-30 | 8.5M | −7.2M | −45.72% |
| Q1 2020 | 2020-03-31 | 49.4M | 49.2M | +31230.43% |
| Q4 2019 | 2019-12-31 | 8.5M | 7.9M | +1246.02% |
| Q3 2019 · Nov 1 | 2019-11-01 | 1.6M | 966,273.2 | +158.67% |
| Q3 2019 · Oct 31 | 2019-10-31 | 15.7M | 15.4M | +4733.19% |
| Q3 2019 · Sep 30 | 2019-09-30 | 157,524.6 | 4,581.9 | +3.00% |
| Q2 2019 | 2019-06-30 | 633,832 | 480,894.18 | +314.44% |
| Q1 2019 | 2019-03-31 | 608,972.8 | 598,492.344 | +5710.56% |
| Q4 2018 | 2018-12-31 | 325,197 | 316,377.113 | +3587.09% |
| As of Nov 28, 2018 | 2018-11-28 | 152,942.7 | 144,931.91 | +1809.21% |
| As of Nov 27, 2018 | 2018-11-27 | 152,937.82 | 145,107.78 | +1853.22% |
| Q3 2018 | 2018-09-30 | 10,480.456 | 2,898.756 | +38.23% |
| Q2 2018 | 2018-06-30 | 8,819.887 | 1,329.736 | +17.75% |
| Q1 2018 | 2018-03-31 | 8,010.79 | 3,849.976 | +92.53% |
| Q4 2017 | 2017-12-31 | 7,830.04 | 3,911.893 | +99.84% |
| Q3 2017 | 2017-09-30 | 7,581.7 | −21,771.018 | −74.17% |
| Q2 2017 | 2017-06-30 | 7,490.151 | −17,589.324 | −70.13% |
| Q1 2017 | 2017-03-31 | 4,160.814 | −14,730.45 | −77.97% |
| Q4 2016 | 2016-12-31 | 3,918.147 | −14,913.522 | −79.19% |
| Q3 2016 | 2016-09-30 | 29,352.718 | 10,521.049 | +55.87% |
| Q2 2016 | 2016-06-30 | 25,079.475 | 8,941.577 | +55.41% |
| Q1 2016 | 2016-03-31 | 18,891.264 | 2,753.366 | +17.06% |
| Q4 2015 | 2015-12-31 | 18,831.669 | 8,026.449 | +74.28% |
| Q3 2015 | 2015-09-30 | 18,831.669 | 8,097.626 | +75.44% |
| Q2 2015 | 2015-06-30 | 16,137.898 | 6,204.792 | +62.47% |
| Q1 2015 | 2015-03-31 | 16,137.898 | 6,235.519 | +62.97% |
| Q4 2014 | 2014-12-31 | 10,805.22 | 4,982.139 | +85.56% |
| Q3 2014 | 2014-09-30 | 10,734.043 | 5,856.553 | +120.07% |
| Q2 2014 | 2014-06-30 | 9,933.106 | 7,735.616 | +352.02% |
| Q1 2014 | 2014-03-31 | 9,902.379 | 7,743.249 | +358.63% |
| Q4 2013 | 2013-12-31 | 5,823.081 | 3,663.951 | +169.70% |
| Q3 2013 | 2013-09-30 | 4,877.49 | −29,400.942 | −85.77% |
| Q2 2013 | 2013-06-30 | 2,197.49 | −32,080.942 | −93.59% |
| Q1 2013 | 2013-03-31 | 2,159.13 | −32,119.302 | −93.70% |
| Q4 2012 | 2012-12-31 | 2,159.13 | −24,907.537 | −92.02% |
| Q3 2012 | 2012-09-30 | 34,278.432 | 16,243.949 | +90.07% |
| Q2 2012 | 2012-06-30 | 34,278.432 | — | — |
| Q1 2012 | 2012-03-31 | 34,278.432 | — | — |
| Q4 2011 | 2011-12-31 | 27,066.667 | — | — |
| Q4 2010 | 2010-12-31 | 18,034.483 | — | — |
Tonix Pharmaceuticals Holding shares outstanding trends
Over the last five reported fiscal years, Tonix Pharmaceuticals Holding's shares outstanding moved from 206.0M to 12.8M, a change of −193.2M. The latest reported quarter, Q2 2026, shows 16.8M.
About the metric
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
Calculation and source
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tonix Pharmaceuticals Holding filings at SEC.gov ↗